Header Logo

Connection

Alan Go to Risk

Back to Details
This is a "connection" page, showing publications Alan Go has written about Risk.
Alan Go
Connection Strength
0.373
Risk
  1. Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA. 2006 Nov 01; 296(17):2105-11.
    View in: PubMed
    Score: 0.064
  2. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. Circulation. 2006 Jun 13; 113(23):2713-23.
    View in: PubMed
    Score: 0.062
  3. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA. 2003 Nov 26; 290(20):2685-92.
    View in: PubMed
    Score: 0.052
  4. Statins for Primary Prevention in Older Adults: Uncertainty and the Need for More Evidence. JAMA. 2016 Nov 15; 316(19):1971-1972.
    View in: PubMed
    Score: 0.032
  5. Long-term survival after ischemic stroke in patients with atrial fibrillation. Neurology. 2014 Mar 25; 82(12):1033-7.
    View in: PubMed
    Score: 0.026
  6. Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol. 2014 Feb; 25(2):349-60.
    View in: PubMed
    Score: 0.026
  7. Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. Circulation. 2013 Aug 13; 128(7):721-8.
    View in: PubMed
    Score: 0.025
  8. Association of single- vs dual-chamber ICDs with mortality, readmissions, and complications among patients receiving an ICD for primary prevention. JAMA. 2013 May 15; 309(19):2025-34.
    View in: PubMed
    Score: 0.025
  9. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA. 2011 Dec 28; 306(24):2673-83.
    View in: PubMed
    Score: 0.023
  10. Cost-effectiveness of using high-sensitivity C-reactive protein to identify intermediate- and low-cardiovascular-risk individuals for statin therapy. Circulation. 2010 Oct 12; 122(15):1478-87.
    View in: PubMed
    Score: 0.021
  11. Susceptibility locus for clinical and subclinical coronary artery disease at chromosome 9p21 in the multi-ethnic ADVANCE study. Hum Mol Genet. 2008 Aug 01; 17(15):2320-8.
    View in: PubMed
    Score: 0.018

© 2024 Kaiser Permanente